Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: A phase 2 trial

Kent A. Robertson, Grzegorz Nalepa, Feng-Chun Yang, Daniel C. Bowers, Chang Y. Ho, Gary D. Hutchins, James M. Croop, Terry A. Vik, Scott C. Denne, Luis F. Parada, Cynthia M. Hingtgen, Laurence E. Walsh, Menggang Yu, Kamnesh R. Pradhan, Mary K. Edwards-Brown, Mervyn D. Cohen, James W. Fletcher, Jeffrey B. Travers, Karl W. Staser, Melissa W. LeeMarcie R. Sherman, Cynthia J. Davis, Lucy C. Miller, David A. Ingram, D. Wade Clapp

Research output: Contribution to journalArticle

113 Scopus citations

Fingerprint Dive into the research topics of 'Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: A phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences